Literature DB >> 18279473

Bromide as marker for drug adherence in hypertensive patients.

Richard L Braam1, Stan H M van Uum, Jacques W M Lenders, Theo Thien.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Insufficient drug adherence is an important reason for inadequate blood pressure control. Currently, methods that measure drug adherence objectively are lacking. Objective methods are needed to help improve blood pressure control and outcome in hypertensive patients. WHAT THIS STUDY ADDS: Potassium bromide added to antihypertensive drugs can be used to monitor drug adherence in individual patients. However, although this method is objective, it is rather time-, cost- and work-consuming. AIMS Adherence to antihypertensive medication is essential for adequate long-term control of blood pressure (BP). This study investigated different methods of measuring adherence in hypertensive patients.
METHODS: Patients were included if BP was insufficiently controlled on monotherapy. After a placebo period patients were treated with trandolapril 2 mg/verapamil SR 180 mg (TV). BP was determined using a mercury sphygmomanometer and ambulatory BP monitoring. Adherence was measured by capsule counting, electronic registration of pill-box openings and by measuring serum bromide concentrations. Potassium bromide was added to each TV capsule.
RESULTS: Thirty patients participated in the study. Treatment with TV significantly lowered office BP and ambulatory BP. Results for electronic monitoring and adherence based on bromide measurements were comparable. Adherence was slightly higher when assessed by capsule counting.
CONCLUSIONS: Measuring serum bromide concentrations may be suitable for assessment of adherence to drug therapy giving comparable results to electronic monitoring. Using capsule counting, electronic monitoring and measurement of bromide concentrations, nonadherent patients were identified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18279473      PMCID: PMC2432484          DOI: 10.1111/j.1365-2125.2007.03068.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Time to stop counting the tablets?

Authors:  T Pullar; S Kumar; H Tindall; M Feely
Journal:  Clin Pharmacol Ther       Date:  1989-08       Impact factor: 6.875

2.  Measuring intake of a prescribed medication. A bottle count and a tracer technique compared.

Authors:  H P Roth; H S Caron; B P Hsi
Journal:  Clin Pharmacol Ther       Date:  1970 Mar-Apr       Impact factor: 6.875

3.  The rational clinical examination. Is this patient taking the treatment as prescribed?

Authors:  B J Stephenson; B H Rowe; R B Haynes; W M Macharia; G Leon
Journal:  JAMA       Date:  1993-06-02       Impact factor: 56.272

4.  Minimal doses of digoxin: a new marker for compliance to medication.

Authors:  H Mäenpää; K Javela; J Pikkarainen; M Mälkönen; O P Heinonen; V Manninen
Journal:  Eur Heart J       Date:  1987-10       Impact factor: 29.983

5.  Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale.

Authors:  M T Kim; M N Hill; L R Bone; D M Levine
Journal:  Prog Cardiovasc Nurs       Date:  2000

6.  [Therapy resistant hypertension--significance of electronic compliance monitoring].

Authors:  J Baulmann; R Düsing; H Vetter; Th Mengden
Journal:  Dtsch Med Wochenschr       Date:  2002-11-08       Impact factor: 0.628

7.  Concurrent and predictive validity of a self-reported measure of medication adherence.

Authors:  D E Morisky; L W Green; D M Levine
Journal:  Med Care       Date:  1986-01       Impact factor: 2.983

Review 8.  Monitoring compliance in resistant hypertension: an important step in patient management.

Authors:  Michel Burnier; Valérie Santschi; Bernard Favrat; Hans R Brunner
Journal:  J Hypertens Suppl       Date:  2003-05

Review 9.  Role of patient compliance in clinical pharmacokinetics. A review of recent research.

Authors:  J Urquhart
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

10.  Bromide as a marker to measure adherence to drug therapy.

Authors:  Richard L Braam; Stan H M van Uum; Frans G M Russel; Dorine W Swinkels; Theo Thien
Journal:  Eur J Clin Pharmacol       Date:  2006-03-07       Impact factor: 2.953

View more
  4 in total

1.  Looking back: editors' pick of 2008.

Authors:  Y K Loke; A Somogyi; L D Lewis; M Schachter; A F Cohen; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

2.  Development of a nomogram for the estimation of long-term adherence to clozapine therapy using neutrophil fluorescence.

Authors:  W H Man; A Pérez-Pitarch; I Wilting; E R Heerdink; W W van Solinge; A C G Egberts; A D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2018-04-02       Impact factor: 4.335

Review 3.  Medication Nonadherence, "Professional Subjects," and Apparent Placebo Responders: Overlapping Challenges for Medications Development.

Authors:  David J McCann; Nancy M Petry; Anders Bresell; Eva Isacsson; Ellis Wilson; Robert C Alexander
Journal:  J Clin Psychopharmacol       Date:  2015-10       Impact factor: 3.153

4.  Effect of garlic powder consumption on body composition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.

Authors:  Davood Soleimani; Zamzam Paknahad; Gholamreza Askari; Bijan Iraj; Awat Feizi
Journal:  Adv Biomed Res       Date:  2016-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.